- Home
- GRI vs WNW Comparison
GRI vs WNW Comparison
Compare GRI & WNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- WNW
- Stock Information
- Founded
- GRI 2018
- WNW 2015
- Country
- GRI United States
- WNW China
- Employees
- GRI N/A
- WNW N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- WNW Catalog/Specialty Distribution
- Sector
- GRI Health Care
- WNW Consumer Discretionary
- Exchange
- GRI Nasdaq
- WNW Nasdaq
- Market Cap
- GRI 3.0M
- WNW 2.5M
- IPO Year
- GRI N/A
- WNW 2020
- Fundamental
- Price
- GRI $0.77
- WNW $0.85
- Analyst Decision
- GRI Strong Buy
- WNW
- Analyst Count
- GRI 1
- WNW 0
- Target Price
- GRI $12.00
- WNW N/A
- AVG Volume (30 Days)
- GRI 9.9M
- WNW 54.4K
- Earning Date
- GRI 11-14-2024
- WNW 11-26-2024
- Dividend Yield
- GRI N/A
- WNW N/A
- EPS Growth
- GRI N/A
- WNW N/A
- EPS
- GRI N/A
- WNW N/A
- Revenue
- GRI N/A
- WNW $380,345.00
- Revenue This Year
- GRI N/A
- WNW N/A
- Revenue Next Year
- GRI N/A
- WNW N/A
- P/E Ratio
- GRI N/A
- WNW N/A
- Revenue Growth
- GRI N/A
- WNW N/A
- 52 Week Low
- GRI $0.30
- WNW $0.71
- 52 Week High
- GRI $106.29
- WNW $11.11
- Technical
- Relative Strength Index (RSI)
- GRI 49.32
- WNW 62.13
- Support Level
- GRI $0.79
- WNW $0.76
- Resistance Level
- GRI $1.00
- WNW $0.83
- Average True Range (ATR)
- GRI 0.17
- WNW 0.04
- MACD
- GRI -0.02
- WNW 0.01
- Stochastic Oscillator
- GRI 24.95
- WNW 75.76
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform, which generates nearly all of its revenue; Restaurant; and Others.